ClinicalTrials.gg

Program

FluBlok

Also written as “UMN-0501”, “Seasonal Influenza Vaccine (SIV) (Flublok)” and “FluBlok®”.

Its studies are mostly in Influenza, Human · Pneumococcal Infections, led by 4 companies.

Furthest: phase 3, since May 17, 20067 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Protein Sciences30 open or runningphase 3since May 17, 2006May 17, 2006none ahead
Shionogi20 open or runningphase 2since Sep 17, 2009Sep 17, 2009none ahead
Sanofi10 open or runningphase 3since Oct 3, 2007Oct 3, 2007none ahead
Vaxcyte10 open or runningphase 3since Jan 22, 2026Jan 22, 2026none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 17, 2006First study: phase 3 study in Influenza, HumanNew to Protein SciencesProtein Sciences · NCT00328107 · 459 enrolled · United States
  2. Oct 3, 2007Sanofi's first study: phase 3 study in Influenza, HumanNew to SanofiSanofi · NCT00539981 · 4,648 enrolled · United States
  3. Oct 4, 2007Phase 3 study in Influenza, HumanProtein Sciences · NCT00539864 · 602 enrolled · United States
  4. Sep 17, 2009Shionogi's first study: phase 2 study in Influenza, HumanNew to ShionogiShionogi · NCT00980447 · 90 enrolled · Japan
  5. Sep 2, 2010Phase 2 study in Influenza, HumanShionogi · NCT01195038 · 87 enrolled · Japan
  6. Mar 11, 2013Phase 3 study in Influenza, HumanProtein Sciences · NCT01825200 · 2,640 enrolled · United States
  7. Jan 22, 2026Vaxcyte's first study: phase 3 study in Pneumococcal InfectionsNew to VaxcyteVaxcyte · NCT07365826 · 1,390 enrolled · United States

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07365826Pneumococcal Infections · United States3CompletedVaxcyteOct 21, 20261,390
NCT01825200Influenza, Human · United States3CompletedProtein SciencesMay 20132,640
NCT01195038Influenza, Human · Japan2CompletedShionogiJan 201187
NCT00980447Influenza, Human · Japan2CompletedShionogiDec 200990
NCT00539864Influenza, Human · United States3CompletedProtein SciencesApr 2008602
NCT00539981Influenza, Human · United States3CompletedSanofiMay 28, 20084,648
NCT00328107Influenza, Human · United States3CompletedProtein SciencesAug 2005459

How it is read

Names in the registry

  • “UMN-0501”, 3 entries
  • “Seasonal Influenza Vaccine (SIV) (Flublok)”, 1 entry
  • “FluBlok®”, 1 entry
  • “Flublok”, 1 entry
  • “FluBlok Influenza Vaccination”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.